Introduction to Oxford Biomedica

Oxford Biomedica (OXB) stands as a pioneering force in the cell and gene therapy sector, headquartered in Oxford, United Kingdom. With over two decades of experience, the company has established itself as a premier viral vector contract development and manufacturing organization (CDMO) and a developer of innovative gene therapies. OXB’s reputation is built on its cutting-edge LentiVector® platform, which enables precise and efficient gene delivery for a wide range of diseases, including rare genetic disorders, oncology, and neurodegenerative conditions. As a top Healthcare company, Oxford Biomedica serves a global clientele, including major pharmaceutical firms and emerging biotechs, by providing end-to-end solutions from process development to commercial-scale manufacturing. The company’s state-of-the-art facilities, combined with a workforce of over 1,500 experts, underline its scale and market leadership. Organizations rely on OXB for its regulatory expertise, robust quality systems, and commitment to accelerating the path from bench to bedside. In an era where personalized medicine is rapidly advancing, Oxford Biomedica remains an indispensable partner in bringing transformative therapies to patients worldwide.

Company History and Business Evolution

Founded in 1995 as a spin-out from Oxford University, Oxford Biomedica initially focused on developing gene therapy treatments for cancer. The early years were marked by pioneering research into viral vectors, particularly lentiviral systems, which would later become the cornerstone of the company’s technology. In 2004, OXB achieved a major milestone by listing on the London Stock Exchange, providing the capital needed to expand its capabilities. The acquisition of the German gene therapy company, Encap, in 2008 strengthened its viral vector expertise. A turning point came in 2016 when Oxford Biomedica signed a landmark licensing and manufacturing agreement with Novartis for the lentiviral vector used in Kymriah, the first CAR-T therapy approved by the FDA. This partnership catapulted OXB into the global spotlight and demonstrated its manufacturing prowess. Since then, the company has undergone rapid expansion: it opened a large-scale manufacturing facility at its Oxford headquarters in 2018, acquired the manufacturing arm of Sanofi in 2020, and formed strategic alliances with numerous biopharma leaders. In 2021, OXB launched its own pipeline of gene therapies for ocular and neurological diseases, while continuing to grow its CDMO business. The company’s evolution from a small research lab to a multinational CDMO and therapeutic developer reflects its adaptability and commitment to excellence. Today, Oxford Biomedica is not only a critical partner for the industry but also a driver of innovation, with multiple clinical trials underway and a robust pipeline of proprietary candidates.

Oxford Biomedica at a Glance

Here are 20 essential facts about Oxford Biomedica:

• Headquarters: Oxford, United Kingdom
• Founded: 1995
• CEO: Dr. Thomas Elsasser (as of 2025)
• Revenue: Approximately £150 million (2024 figures)
• Employees: Over 1,500
• Stock Ticker: OXB (London Stock Exchange)
• Core Technology: LentiVector® lentiviral vector platform
• Industry: Biotechnology – Cell and Gene Therapy
• Key Clients: Novartis, AstraZeneca, Bristol Myers Squibb, Sangamo, etc.
• Manufacturing Capacity: Multiple commercial-scale suites in Oxford and a new facility in France
• Pipeline: Proprietary gene therapies for retinal diseases (e.g., RetinoStat), Parkinson’s disease, and cancer
• Regulatory Approvals: The LentiVector platform is used in approved CAR-T therapies (Kymriah)
• Patents: Over 100 issued and pending patents
• Quality Certifications: ISO 13485, GMP compliance, FDA inspection readiness
• Acquisitions: Encap (2008), Sanofi’s manufacturing arm (2020)
• Funding: Publicly listed with strong institutional investor base
• Global Reach: Clients in North America, Europe, and Asia
• R&D Investment: Over 20% of revenue allocated to R&D
• Major Awards: Queen’s Award for Enterprise (International Trade), 2020
• ESG Commitment: Net-zero emissions target by 2035

Mission, Vision, and Core Corporate Values

Oxford Biomedica’s mission is to “transform the lives of people with serious diseases through the development and manufacture of gene-based medicines.” The company envisions a world where genetic diseases are not only treatable but curable, with advanced therapies accessible to all who need them. This ambitious vision is underpinned by a set of core values that guide every aspect of the organization:

• Innovation: Constantly pushing the boundaries of vector technology to overcome delivery challenges.
• Quality: Uncompromising commitment to regulatory standards and patient safety.
• Collaboration: Partnering with clients, academia, and regulators to accelerate development.
• Integrity: Transparent communication and ethical decision-making.
• People First: Valuing employees, their well-being, and their professional growth.
• Patient Centricity: Keeping the ultimate goal—patient benefit—at the heart of every project.

Business Strategy and Future Roadmap

Oxford Biomedica’s strategy is twofold: to grow its CDMO business and to advance its proprietary pipeline of gene therapies. On the CDMO side, the company plans to expand manufacturing capacity through a state-of-the-art facility in France (2025) and enhance its process development capabilities to support clients from preclinical to commercial. It also aims to diversify its vector offerings, including adeno-associated virus (AAV) and gamma-retroviral vectors, complementing its established lentiviral expertise. On the proprietary side, OXB is prioritizing ocular gene therapies—starting with retinitis pigmentosa and wet AMD—and neurodegenerative conditions like Parkinson’s disease, leveraging its LentiVector platform for sustained expression. The company also explores partnerships for oncology combination therapies. Strategic acquisitions remain on the table to acquire new technologies or manufacturing capacity. With the gene therapy market projected to grow at a CAGR of 19% to $25 billion by 2030, Oxford Biomedica is well-positioned to capture significant market share through its integrated offerings and reputation for cGMP excellence.

Products, Technologies, and Services

Oxford Biomedica’s primary offering is its LentiVector® platform, a lentiviral vector system that delivers genetic payloads with high efficiency and long-term expression. This platform is used both internally and by partners for applications in CAR-T cell therapy, gene editing, and gene replacement. Key product categories include:

• Lentiviral Vector Manufacturing: Process development, scale-up, and commercial production under cGMP.
• AAV Vector Manufacturing: A newer offering leveraging expertise in suspension cell culture.
• Contract Process Development: Analytical method development, formulation, and stability testing.
• Analytical Services: Potency, identity, purity, and safety assays (including ELISA, qPCR, and NGS).
• Proprietary Therapies: OXB-102 for Parkinson’s disease, OXB-202 for retinal disease, and OXB-401 for cancer (preclinical).
• Licensing: Non-exclusive and exclusive licenses to LentiVector technology for specific targets.

Additionally, OXB provides regulatory consultancy, helping clients navigate FDA and EMA guidelines for gene therapy products. The combination of vector design, platform validation, and manufacturing scalability makes OXB a one-stop shop for gene therapy developers.

Industries and Markets Served

Oxford Biomedica primarily serves the pharmaceutical and biotechnology industries, with a focus on companies developing cell and gene therapies. Its clients range from small startups to the world’s top 20 pharma companies. The therapies enabled by OXB cover multiple therapeutic areas:

• Oncology: CAR-T and TCR therapies for hematologic and solid tumors.
• Neurology: Gene therapies for Parkinson’s, Alzheimer’s, and Huntington’s disease.
• Ophthalmology: Treatments for inherited retinal dystrophies and age-related macular degeneration.
• Rare Genetic Diseases: Metabolic disorders, lysosomal storage diseases, and hemophilia.
• Infectious Diseases: Vaccines based on viral vectors (including COVID-19 collaborations).

Geographically, OXB serves clients in North America (40% of revenue), Europe (35%), and the rest of the world including Asia-Pacific (25%). The company also collaborates with academic institutions and non-profit foundations to advance gene therapy science.

Leadership and Management Philosophy

Oxford Biomedica’s leadership team combines deep scientific expertise with business acumen. CEO Dr. Thomas Elsasser, appointed in 2023, brings over 25 years of experience in the biotech industry, including senior roles at Roche and Novartis. The management philosophy at OXB centers on servant leadership—empowering teams, fostering open communication, and encouraging cross-functional collaboration. Decision-making is data-driven but agile, with an emphasis on speed without compromising quality. The company invests heavily in talent development through continuous learning programs, mentoring, and leadership training. Ethical considerations are paramount: the leadership champions diversity, equity, and inclusion, with a goal of 40% female representation in management by 2026. Regular town halls and transparent reporting of company performance ensure that employees feel connected to the corporate vision. Underpinning it all is a culture of relentless innovation—employees are encouraged to propose new ideas and challenge the status quo.

Corporate Events, Conferences, and Community Engagement

Oxford Biomedica actively participates in major gene therapy conferences, such as the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, the Cell & Gene Therapy World Congress, and the International Society for Cell & Gene Therapy (ISCT) conferences. The company often presents data on its manufacturing innovations, vector design, and clinical progress. Additionally, OXB hosts its own annual symposium, the LentiVector Summit, bringing together industry leaders, academics, and regulators to discuss vector technology challenges and breakthroughs. Community engagement is a priority: the company sponsors local STEM education initiatives in Oxfordshire, supports the Oxford Gene Therapy Society, and partners with charities like the Cure Parkinson’s Trust. Employee volunteering days are encouraged, and OXB matches charitable donations up to a certain amount. The company also runs an internship program for undergraduates and postgraduates, nurturing the next generation of gene therapy scientists.

Employees and Workplace Culture

With over 1,500 employees, Oxford Biomedica fosters a collaborative, inclusive, and innovative workplace. The culture is described as “fast-paced but supportive,” with a strong sense of shared purpose. Employees enjoy:

• Flexible working arrangements (hybrid options for office-based roles).
• Competitive salaries and benefits, including pension contributions, private health insurance, and bonus plans.
• Extensive training and development programs, including access to online courses and conference attendance.
• State-of-the-art laboratories and manufacturing facilities designed for safety and efficiency.
• Employee resource groups for women in STEM, LGBTQ+, and mental well-being.
• Regular social events, team outings, and wellness initiatives (e.g., yoga sessions, gym subsidies).

Turnover is low compared to industry averages, reflecting high employee engagement. The company regularly appears on lists of top employers in the UK biotech sector.

Job Details & Requirements for this Posting (Senior Process Development Scientist)

Role: Oxford Biomedica is seeking a Senior Process Development Scientist to join its Viral Vector Process Development team. This role is based at our Oxford facility and reports to the Associate Director of Process Development.

Responsibilities:

• Design and execute experiments to develop, optimize, and scale-up lentiviral vector production processes (upstream and downstream).
• Analyze data using statistical tools (e.g., JMP, Design-Expert) and present findings to internal teams and clients.
• Author technical reports, batch records, and regulatory submission documents.
• Lead technology transfer activities to internal manufacturing suites or partner CDMOs.
• Mentor junior scientists and contribute to a culture of scientific excellence.
• Collaborate with analytical development to ensure robust product characterization.

Qualifications:

• PhD in Biochemistry, Biotechnology, or related field, OR MSc with 3+ years of relevant experience in viral vector manufacturing.
• Hands-on experience with mammalian cell culture (HEK293, suspension cells) and purification techniques (TFF, AEX, SEC).
• Proficiency in viral vector analytics (qPCR, ELISA, infectivity assays).
• Strong understanding of cGMP regulations and quality by design (QbD) principles.
• Excellent communication skills and ability to work cross-functionally.
• Leadership potential and enthusiasm for mentoring.

Why join Oxford Biomedica? You will work on cutting-edge technology that directly impacts patients, collaborate with world-class experts, and have access to unrivaled facilities. The company offers a clear career progression path, with opportunities to move into senior leadership roles. Additionally, Oxford Biomedica provides a supportive environment that values work-life balance and professional growth.

Customer Reviews and Industry Reputation

Oxford Biomedica enjoys a strong reputation in the gene therapy community. Below we examine feedback from multiple platforms:

Glassdoor

On Glassdoor, Oxford Biomedica holds an overall rating of 4.1 out of 5 stars, based on over 300 reviews. Employees frequently praise the meaningful work, passionate colleagues, and strong leadership. Common positives include “cutting-edge science,” “opportunities to learn,” and “great benefits.” Some critiques mention occasional bureaucracy and pressure during client deadlines. The CEO approval rating is high at 89%. The company is especially well-rated for culture and values (4.3/5).

Indeed

Indeed reviews give an average of 4.0 out of 5. Many reviewers highlight the quality of training and supportive management. One scientist wrote: “I’ve grown more in two years here than in five years elsewhere.” Negative feedback often centers on workload during peak periods, but overall sentiment remains positive. The company is recommended by 82% of Indeed reviewers.

Gartner Peer Insights

While Gartner primarily covers IT, Oxford Biomedica is occasionally reviewed under “CDMO services.” Customers rate it highly for reliability and regulatory compliance. One client stated: “Oxford Biomedica’s ability to scale our process from 50L to 500L without issues was impressive. Their project management team kept us informed at every step.” Ratings average 4.5/5.

Trustpilot

Trustpilot reviews are more limited but generally positive (4.2/5). Partners appreciate transparent communication and technical expertise. A small number of negative reviews mention pricing, but most acknowledge that the quality justifies the cost.

G2

G2 reviews for the “Cell and Gene Therapy CDMO” category place Oxford Biomedica among the top three. Users highlight the LentiVector platform’s stability and the company’s willingness to innovate. One reviewer noted: “They helped us modify our vector design to improve yield by 30%.”

Google Reviews

Google Reviews for the Oxford facility average 4.6/5, with visitors impressed by the modern campus and friendly staff. Employees often leave positive notes about the free coffee and ergonomic labs.

LinkedIn Reputation

On LinkedIn, Oxford Biomedica has a strong presence with over 80,000 followers. Employee advocacy is high; many post about achievements and their pride in working there. The company is frequently listed as a “Great Place to Work” in listicles covering biopharma.

Why Organizations Choose Oxford Biomedica

Organizations partner with Oxford Biomedica for several key reasons: unparalleled expertise in lentiviral vectors, a track record of regulatory success (including the first ever CAR-T therapy), and the ability to handle complex large-scale manufacturing. OXB’s early involvement in a client’s program can reduce development timelines by up to 18 months. The company also offers flexible business models—fee-for-service, profit-sharing, or equity-based partnerships—accommodating different client risk profiles. Furthermore, OXB’s commitment to quality and its global reach make it a reliable partner for global clinical trials and commercialization. Customers consistently cite transparency, technical depth, and a collaborative approach as reasons for long-term loyalty.

Official Contact Information

For inquiries and assistance, please reach out to Oxford Biomedica using the following contact details:

Address: Medawar Building, Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GA, United Kingdom
Contact Number: +44 (0)1865 783000
Support Number: +44 (0)1865 783001
Helpdesk Number: +44 (0)1865 783002
Website: https://www.oxfordbiomedica.com/

Official Social Media Presence

Stay connected with Oxford Biomedica on social media:

• LinkedIn
• X (Twitter)
• YouTube

SEO FAQ Section

1. What is Oxford Biomedica's core business?

Oxford Biomedica (OXB) specializes in the development and manufacture of viral vectors for gene therapy, particularly using its LentiVector® lentiviral platform, and also advances its own pipeline of gene therapies.

2. Where is Oxford Biomedica headquartered?

Oxford Biomedica’s global headquarters is located in Oxford, United Kingdom, at the Oxford Science Park.

3. Is Oxford Biomedica a publicly traded company?

Yes, Oxford Biomedica is listed on the London Stock Exchange under the ticker symbol OXB.

4. What is the LentiVector® platform?

The LentiVector® platform is Oxford Biomedica’s proprietary lentiviral vector system designed to deliver therapeutic genes efficiently and safely into target cells.

5. How many employees does Oxford Biomedica have?

As of 2025, Oxford Biomedica employs approximately 1,500 people worldwide, including scientists, engineers, and support staff.

6. What types of gene therapies does Oxford Biomedica work on?

Oxford Biomedica develops therapies for oncology (CAR-T), neurology (Parkinson’s), ophthalmology (retinal diseases), and rare genetic disorders.

7. Does Oxford Biomedica manufacture for other companies?

Yes, Oxford Biomedica operates as a contract development and manufacturing organization (CDMO), producing viral vectors for pharmaceutical and biotech partners.

8. What is Oxford Biomedica’s annual revenue?

Oxford Biomedica reported annual revenue of around £150 million in its most recent fiscal year.

9. Who is the CEO of Oxford Biomedica?

The CEO of Oxford Biomedica is Dr. Thomas Elsasser, who took the role in 2023.

10. How can I contact Oxford Biomedica for business inquiries?

You can reach Oxford Biomedica via their website or by calling +44 (0)1865 783000 for general inquiries.

11. What certifications does Oxford Biomedica hold?

Oxford Biomedica is ISO 13485 certified and operates under current Good Manufacturing Practice (cGMP) standards, with facilities regularly inspected by the FDA and EMA.

12. Does Oxford Biomedica offer internships?

Yes, Oxford Biomedica runs a structured internship program for undergraduate and postgraduate students in scientific and commercial roles.

13. What is Oxford Biomedica's approach to ESG?

Oxford Biomedica is committed to achieving net-zero emissions by 2035 and has implemented sustainable manufacturing practices, waste reduction, and diversity initiatives.

14. Which major companies have partnered with Oxford Biomedica?

Notable partners include Novartis (for Kymriah), AstraZeneca, Bristol Myers Squibb, and Sangamo Therapeutics.

15. What is the work culture like at Oxford Biomedica?

Employees describe a collaborative, innovative culture with a strong sense of purpose, supported by flexible working and professional development opportunities.

16. Are there opportunities to work remotely at Oxford Biomedica?

Oxford Biomedica offers hybrid working arrangements for certain roles, but lab-based positions require on-site presence.

17. How long has Oxford Biomedica been in business?

Oxford Biomedica was founded in 1995, meaning it has been operating for over 30 years.

18. Does Oxford Biomedica have a pipeline of proprietary therapies?

Yes, Oxford Biomedica is developing proprietary gene therapies for Parkinson’s disease (OXB-102), retinal diseases (OXB-202), and cancer (OXB-401).

19. What is the salary range for a Senior Scientist at Oxford Biomedica?

Salaries for Senior Scientists typically range from £55,000 to £75,000 per year, depending on experience and qualifications.

20. How does Oxford Biomedica ensure product quality?

Oxford Biomedica employs robust quality management systems, extensive in-process testing, and a dedicated Quality Assurance team to ensure compliance with global regulatory standards.

For professionals seeking to stay ahead in the dynamic field of gene therapy and digital marketing, exploring external resources can be invaluable. For instance, Oxford Biomedica itself is a leading authority in viral vector manufacturing. Additionally, companies looking to enhance their online visibility and establish thought leadership can benefit from High DA Guest Posting Sites through professional guest posting services. Whether you need Guest Posting or Guest Posting Services, platforms like BipBipAmerica offer tailored solutions. Their Guest Post Service and Guest Blogging Services help businesses secure premium placements. For those wanting to Submit Guest Post or Buy Guest Posts, the provider offers Paid Guest Posting with attractive Guest Post Packages. Through Guest Post Outreach, you can leverage High DA Guest Posting Sites to boost SEO. Their SEO Guest Posting Services and role as a Guest Posting Agency ensure quality Guest Post Backlinks. Whether you opt for Premium Guest Posts, Instant Guest Posting, or Publish Guest Posts, their Sponsored Guest Posts provide immediate impact. Integrating such services can complement a robust corporate content strategy.